[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616320":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":36,"locations":42,"responsibleParty":99,"collaborators":35,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":35,"eligibilityCriteria":106,"healthyVolunteers":103,"sex":107,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":35,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":45,"whyStopped":35,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Jaseng Medical Foundation","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hominis placental pharmacopuncture","EXPERIMENTAL","Participants in the experimental group will receive JHG002 pharmacopuncture twice weekly for 5 weeks (total 10 sessions). JHG002 (0.05-0.1 mL per point) will be administered to 8-10 acupuncture points commonly used for chronic low back pain, including BL23, BL24, BL25, GV3, and GV4, with optional GB30 based on symptoms.",[13],"Drug: Hominis placental pharmacopuncture",{"label":15,"type":16,"description":17,"interventionNames":18},"Physical Therapy Group","ACTIVE_COMPARATOR","Participants in the control group will receive standardized transcutaneous electrical nerve stimulation (TENS) therapy twice weekly for 5 weeks (total 10 sessions). Each session will last 15 minutes and will be administered using a unified protocol across all participating sites to target the lumbar region.",[19],"Device: Tanscutaneous electrical nerve stimulation (TENS)",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","JHG002 pharmacopuncture is a purified Hominis placenta extract formulated for injection at acupuncture points. In Korean medicine, Hominis placenta has traditionally been used to support vitality, relieve chronic pain, and enhance functional recovery.",[9],[26],"JHG002",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DEVICE","Tanscutaneous electrical nerve stimulation (TENS)","Transcutaneous electrical nerve stimulation is a non-invasive physical therapy that delivers low-intensity electrical stimulation to the lumbar area to reduce pain and muscle tension.",[15],[33,34],"TENS","electrical nerve stimulation",null,[37],{"name":38,"role":39,"phone":40,"phoneExt":35,"email":41},"In-Hyuk Ha, Dr","CONTACT","+82-1577-0007","hanihata@gmail.com",[43,61,72,85],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":35,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Kyung Hee University Korean Medicine Hospital at Gangdong","RECRUITING","Seoul","Gangdong-gu","05278","South Korea",{"type":51,"coordinates":52},"Point",[53,54],126.9784,37.566,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":59,"phoneExt":35,"email":60},"Yeon-Chul Park, KMD","+82-10-3395-1075","icarus08@hanmail.net",{"facility":62,"status":45,"city":46,"state":63,"zip":64,"country":49,"countryCode":35,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"Jaseng Hospital of Korean Medicine","Gangnam-Gu","06110",{"type":51,"coordinates":66},[53,54],{"lat":54,"lon":53},[69],{"name":70,"role":39,"phone":40,"phoneExt":35,"email":71},"Yong-Jun Ahn, KMD","ahnyj322@gmail.com",{"facility":73,"status":45,"city":74,"state":75,"zip":76,"country":49,"countryCode":35,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Bucheon Jaseng Hospital of Korean Medicine","Bucheon-si","GGyeonggi-do","14598",{"type":51,"coordinates":78},[79,80],126.78306,37.49889,{"lat":80,"lon":79},[83],{"name":84,"role":39,"phone":40,"phoneExt":35,"email":41},"In-Hyuk Ha, KMD",{"facility":86,"status":45,"city":87,"state":75,"zip":88,"country":49,"countryCode":35,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Dongguk University Bundang Oriental Hospital","Seongnam","13601",{"type":51,"coordinates":90},[91,92],127.7548,36.4052,{"lat":92,"lon":91},[95],{"name":96,"role":39,"phone":97,"phoneExt":35,"email":98},"Eunjung Kim, KMD","+82-10-5948-1075","hanijung@naver.com",{"type":100,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100616320","clinical-research-on-the-comparative-effectiveness-and-safety-of-jhg002-therapy-for-chronic-low-back-pain-a-multicenter-randomized-controlled-trial-100616320",false,"NCT07304076","Clinical Research on the Comparative Effectiveness and Safety of JHG002 Therapy for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 19 to 69 years at the time of signing the informed consent.\n* Individuals who have experienced low back pain for ≥6 months, presenting with either continuous or intermittent symptoms.\n* Participants with a Numeric Rating Scale (NRS) score ≥ 5 for low back pain at screening.\n* Individuals who fully understand the clinical trial procedures and voluntarily agree to participate by providing written informed consent.\n\nExclusion Criteria:\n\n* Patients diagnosed with serious underlying conditions that may cause low back pain, such as spinal metastasis of malignancy, acute vertebral fracture, or spinal dislocation.\n* Patients with progressive neurological deficits or those presenting with severe neurological symptoms.\n* Patients whose pain originates from non-spinal soft tissue disorders, including tumors, fibromyalgia, rheumatoid arthritis, or gout.\n* Individuals with other chronic medical conditions that may interfere with treatment response or interpretation of study outcomes, such as stroke, myocardial infarction, chronic kidney disease, diabetic neuropathy, dementia, or epilepsy.\n* Individuals currently taking corticosteroids, immunosuppressants, psychiatric medications, or any other drugs that may influence study results.\\*\n* Patients for whom pharmacopuncture is inappropriate or unsafe, including those with bleeding disorders or those receiving anticoagulant therapy.\n* Individuals who have taken analgesic medications such as NSAIDs or received pharmacopuncture treatment within the past 1 week.\n* Women of childbearing potential who are unwilling to use medically acceptable contraception (e.g., surgical sterilization, intrauterine device, condom or diaphragm use, injectable or implantable contraceptives) throughout the study period.\n* Pregnant or breastfeeding women.\n* Individuals with a history of hypersensitivity or allergic reactions to Hominis placenta pharmacopuncture (JHG002).\n* Patients with uncontrolled diabetes mellitus (fasting blood glucose ≥ 180 mg\u002FdL).\n* Individuals whose AST (GOT) or ALT (GPT) levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Individuals whose serum creatinine levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Patients suspected of having an underlying organic disease.\n* Patients with moderate systemic complications involving organs other than the heart, liver, or kidneys.\n* Patients with psychogenic disorders.\n* Individuals with an implanted cardiac pacemaker.\n* Patients with inflammation, infection, wounds, or other lesions at the planned pharmacopuncture sites that would prevent safe administration.\n* Patients within 3 months after lumbar spine surgery.\n* Individuals who have participated in another clinical trial within the past 1 month, or who plan to participate in another clinical trial-including follow-up periods-within 6 months from the screening date.\n* Any individual deemed unsuitable for participation in this study by the investigator.","ALL","19 Years","70 Years",{"count":111,"type":112},96,"ESTIMATED","INTERVENTIONAL",[115],"NA","A multicenter randomized controlled trial",[118],"Chronic Low Back Pain (CLBP)",[120,121],"chronic low back pain","pharmacopuncture","2026-02-24",{"date":124,"type":125},"2026-02-25","ACTUAL",{"date":127,"type":125},"2025-12-17",{"date":129,"type":112},"2029-11-28",{"name":5,"class":6},4]